Consumption of psychoactive substances in prison: Between initiation and improvement, what trajectories occur after incarceration? COSMOS study data

English version

Autoři: Morgane Rousselet ^aff001; Marylène Guerlais ^aff001; Pascal Caillet ^aff001; Bertrand Le Geay ^aff004; Damien Mauillon ^aff005; Patrick Serre ^aff006; Pierre-Yves Chameau ^aff007; Yves Bleher ^aff008; Serge Mounsande ^aff009; Pascale Jolliet ^aff001; Caroline Victorri-Vigneau ^aff001
Působiště autorů: Centre for Evaluation and Information on Pharmacodependence, Clinical Pharmacology Department, Nantes University Hospital, France ^aff001; INSERM U1246 SPHERE “methodS in Patient-centered outcomes and HEalth ResEarch”, Nantes and Tours University, Nantes, France ^aff002; Addictology and Psychiatry Department, University Hospital, Nantes, France ^aff003; Department of Prison Psychiatry, Nantes University Hospital, France ^aff004; Medical department of prison, Angers University Hospital, France ^aff005; Medical department of prison, Le Mans HospitalFrance ^aff006; Medical department of prison, Laval Hospital, France ^aff007; Medical department of prison, La Roche sur Yon Departemental Hospital, Boulevard Stéphane Moreau, France ^aff008; Medical department of prison, Fontenay-Le-Comte Hospital, France ^aff009
Vyšlo v časopise: PLoS ONE 14(12)
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pone.0225189

Souhrn

Background

Few studies have examined the consumption trajectories of inmates after entry to prison. The aim of this study was to assess the changes in the consumption of psychoactive substance between the period before detention and during incarceration and to characterize the profiles of prisoners with similar consumption trajectories during incarceration.

Methods and findings

A multicenter, cross-sectional study was performed in all of the prisons from one region of France. All prisoners incarcerated during their 3rd months, over 18 years old, and with a sufficient level of French fluency to participate in the study were recruited over a period of 12 months. A total of 800 prisoners were recruited. All prisoners were interviewed face-to-face by a trained interviewer. A majority of prisoners had used at least one psychoactive substance in the weeks prior to incarceration. During incarceration, a substantial reduction in alcohol and illicit drug consumption was observed. The initiation of consumption and an increase in consumption were primarily related to medications. Five different profiles of consumption before incarceration were identified. These profiles all had a high probability of migrating to a similar profile during detention, characterized by less severe consumption of psychoactive substances.

Conclusions

Based on their consumption profile prior to incarceration, most prisoners would benefit from a specific medical evaluation as soon as possible following entry into detention. Prison could be an opportunity for reduced consumption and/or the initiation of treatment for the majority of prisoners, despite the pejorative development observed for a minority of prisoners during incarceration.

Klíčová slova:

Alcohol consumption – Prisons – Prisoners – Recreational drug use – Cannabis – Questionnaires – Cocaine – Heroin

Zdroje

1. Hyest J, Cabanel G. Conditions of life in french jails, report of inquiry commission in the french Senat n°449. https://wwwsenatfr/rap/l99-449/l99-449html. 1999.

2. Bouhnik P, Jacob E, Maillard I, Touzé S. The amplification of risks among drugs users: prison-polyconsumption- maintenance treatment, RESSCOM survey. http://dochubsanteorg/doc_numphp?explnum_id=14228. 1999.

3. Mouquet M. French direction of research, studies, evaluation and statistics: health of inmates who arrived in jail in 2003. http://dreessolidarites-santegouvfr/etudes-et-statistiques/publications/etudes-et-resultats/article/la-sante-des-personnes-entrees-en-prison-en-2003. 2005.

4. Falissard B, Loze JY, Gasquet I, Duburc A, de Beaurepaire C, Fagnani F, et al. Prevalence of mental disorders in French prisons for men. BMC Psychiatry. 2006;6:33. doi: 10.1186/1471-244X-6-33 16923177.

5. Sahajian F, Lamothe P, Fabry J. [Psychoactive substance use among newly incarcerated prison inmates]. Sante Publique. 2006;18(2):223–34. doi: 10.3917/spub.062.0223 16886546.

6. Lukasiewicz M, Falissard B, Michel L, Neveu X, Reynaud M, Gasquet I. Prevalence and factors associated with alcohol and drug-related disorders in prison: a French national study. Subst Abuse Treat Prev Policy. 2007;2:1. doi: 10.1186/1747-597X-2-1 17204156.

7. Marzo JN, Rotily M, Meroueh F, Varastet M, Hunault C, Obradovic I, et al. Maintenance therapy and 3-year outcome of opioid-dependent prisoners: a prospective study in France (2003–06). Addiction. 2009;104(7):1233–40. doi: 10.1111/j.1360-0443.2009.02558.x 19426291.

8. Sahajian F, Lamothe P, Fabry J, Vanhems P. Consumption of psychoactive substances among 535 women entering a Lyon prison (France) between June 2004 and December 2008. Rev Epidemiol Sante Publique. 2012;60(5):371–81. doi: 10.1016/j.respe.2012.02.010 22981309.

9. Sannier O, Verfaillie F, Lavielle D. Risk reduction and drug use in detention: study about the detainees of Liancourt Penitentiary. Presse Med. 2012;41(7–8):e375–85. doi: 10.1016/j.lpm.2011.12.015 22386285.

10. Rossard P, Riuné-Lacabe S, Cousin P, Denis C, Auriacombe M. Substance use and risk behavior during incarceration, survey in a french jail. Le courrier des addictions: http://wwwedimarkfr/Front/frontpost/getfiles/18631pdf. 2012;14(2):28–30.

11. Sahajian F, Berger-Vergiat A, Pot E. Use of psychoactive substances in prison: Results of a study in the Lyon-Corbas prison, France. Rev Epidemiol Sante Publique. 2017;65(5):361–7. doi: 10.1016/j.respe.2017.05.007 28886958.

12. Fazel S, Bains P, Doll H. Substance abuse and dependence in prisoners: a systematic review. Addiction. 2006;101(2):181–91. doi: 10.1111/j.1360-0443.2006.01316.x 16445547.

13. Michel L. Drug use in prisons: strategies for harm reduction (ANRS-PRIDE Program). Cien Saude Colet. 2016;21(7):2081–8. doi: 10.1590/1413-81232015217.28442015 27383342.

14. Michel L, Trouiller P, Chollet A, Molinier M, Duchesne L, Jauffret-Roustide M. Self-reported injection practices among people who use drugs in French prisons: Public health implications (ANRS-Coquelicot survey 2011–2013). Drug Alcohol Rev. 2018;37 Suppl 1:S268–S76. doi: 10.1111/dar.12620 29105203.

15. Semaille C, Le Strat Y, Chiron E, Chemlal K, Valantin MA, Serre P, et al. Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy. Euro Surveill. 2013;18(28). doi: 10.2807/1560-7917.es2013.18.28.20524 23870097.

16. INSERM. [Psychotropic drugs: consumptions and pharmacodependences.]. Paris: 2012.

17. French Ministry of Health and Social Protection FMoJ. Methodological Guide of Health Care on inmates. http://solidarites-santegouvfr/IMG/pdf/Guide_methodologique_relatif_a_la_prise_en_charge_sanitaire_des_personnes_detenuespdf. 2004.

18. Michel L, Jauffret-Roustide M, Blanche J, Maguet O, Calderon C, Cohen J, et al. Limited access to HIV prevention in French prisons (ANRS PRI2DE): implications for public health and drug policy. BMC Public Health. 2011;11:400. doi: 10.1186/1471-2458-11-400 21619573.

19. Jauffret-Roustide M, Emmanuelli J, Quaglia M, Barin F, Arduin P, Laporte A, et al. Impact of a harm-reduction policy on HIV and hepatitis C virus transmission among drug users: recent French data—the ANRS-Coquelicot Study. Subst Use Misuse. 2006;41(10–12):1603–21. doi: 10.1080/10826080600847951 17002994.

20. Jauffret-Roustide M, Emmanuelli J, Desenclos JC. [Limited impact of the harm-reduction policy on HCV among drug-users. The ANRS-Coquelicot survey example]. Rev Epidemiol Sante Publique. 2006;54 Spec No 1:1S53–1S9. 17073130.

21. Inserm. French. Expertise Inserm. Reduction of infectious risks among drugs users. http://wwwipubliinsermfr/handle/10608/86. 2010;(ch.18):309–40.

22. French Ministry of Health and Social Protection FMoJ. Guide of opioid maintenance treatment in prison. http://solidarites-santegouvfr/IMG/pdf/Guide_des_TSO_en_milieu_carceralpdf. 2013.

23. Jouanjus E, Gibaja V, Kahn JP, Haramburu F, Daveluy A. Signal identification in addictovigilance: the functioning of the French system. Therapie. 2015;70(2):113–31. doi: 10.2515/therapie/2015011 25858567.

24. Micallef J, Mallaret M. Twenty-five years of the French Addictovigilance Network (FAN). Therapie. 2016;71(4):375–8. doi: 10.1016/j.therap.2016.05.001 27296806.

25. Nordmann S, Frauger E, Pauly V, Rouby F, Mallaret M, Micallef J, et al. Post-marketing surveillance systems for psychoactive prescription drug abuse. Therapie. 2011;66(3):263–72. doi: 10.2515/therapie/2011045 21819810.

26. Pauly V, Frauger E, Rouby F, Sirere S, Monier S, Paulet C, et al. Analysis of addictive behaviours among new prisoners in France using the OPPIDUM program. Encephale. 2010;36(2):122–31. doi: 10.1016/j.encep.2009.03.011 20434629.

27. Lanza ST, Rhoades BL. Latent class analysis: an alternative perspective on subgroup analysis in prevention and treatment. Prev Sci. 2013;14(2):157–68. doi: 10.1007/s11121-011-0201-1 21318625.

28. Collins LM, Lanza ST. Latent class and latent transition analysis: with applications in the social, behavioral, and health sciences. Wiley, editor. New-York2010.

29. Observatoire français des drogues et des toxicomanies OFDT. [Drugs, Key figures.]. 2017.

30. French ministry of justice. [Prevention of recidivism and individualization of sentences, key figures.]. 2014.

31. Wakeman SE. Why It's Inappropriate Not to Treat Incarcerated Patients with Opioid Agonist Therapy. AMA J Ethics. 2017;19(9):922–30. doi: 10.1001/journalofethics.2017.19.9.stas1-1709 28905733.

32. Observatoire français des drogues et des toxicomanies OFDT. [Social characteristics, consumption and risks among drug users attending needle exchange programs in France.]. 1999.

33. Al-Rousan T, Rubenstein L, Sieleni B, Deol H, Wallace RB. Inside the nation's largest mental health institution: a prevalence study in a state prison system. BMC Public Health. 2017;17(1):342. doi: 10.1186/s12889-017-4257-0 28427371.

34. Kouyoumdjian FG, Calzavara LM, Kiefer L, Main C, Bondy SJ. Drug use prior to incarceration and associated socio-behavioural factors among males in a provincial correctional facility in Ontario, Canada. Can J Public Health. 2014;105(3):e198–202. doi: 10.17269/cjph.105.4193 25165839.

35. Wiley A, O'Neill S. Alcohol, Tobacco and Other Drugs Nursing within a Correctional Setting. Aust Nurs Midwifery J. 2016;24(6):39. 29251892.

36. Fazel S, Ramesh T, Hawton K. Suicide in prisons: an international study of prevalence and contributory factors. Lancet Psychiatry. 2017;4(12):946–52. doi: 10.1016/S2215-0366(17)30430-3 29179937.

37. Albertie A, Bourey C, Stephenson R, Bautista-Arredondo S. Connectivity, prison environment and mental health among first-time male inmates in Mexico City. Glob Public Health. 2017;12(2):170–84. doi: 10.1080/17441692.2015.1091023 26465257.

38. Caravaca-Sanchez F, Falcon Romero M, Luna A. [Prevalence and predictors of psychoactive substance use among men in prisons]. Gac Sanit. 2015;29(5):358–63. doi: 10.1016/j.gaceta.2015.06.005 26228003.

39. Rubenstein LS, Amon JJ, McLemore M, Eba P, Dolan K, Lines R, et al. HIV, prisoners, and human rights. Lancet. 2016;388(10050):1202–14. doi: 10.1016/S0140-6736(16)30663-8 27427457.

40. Wright NM, Tompkins CN, Farragher TM. Injecting drug use in prison: prevalence and implications for needle exchange policy. Int J Prison Health. 2015;11(1):17–29. doi: 10.1108/IJPH-09-2014-0032 25751704.

41. Jurgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis. 2009;9(1):57–66. doi: 10.1016/S1473-3099(08)70305-0 19095196.

42. Shewan D, Gemmell M, Davies JB. Behavioural change amongst drug injectors in Scottish prisons. Soc Sci Med. 1994;39(11):1585–6. doi: 10.1016/0277-9536(94)90010-8 7817222.

43. Dewa LH, Hassan L, Shaw JJ, Senior J. Insomnia management in prisons in England and Wales: a mixed-methods study. J Sleep Res. 2017;26(3):322–9. doi: 10.1111/jsr.12503 28239925.